![]() Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases. | ![]() Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases. | |||
Founding Date | Founding Date 2016 | Founding Date 2002 | Founding Date 1992 | Founding Date 2010 |
Type | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Oakland, US HQ | Locations Philadelphia, US HQ Northbridge, AU Pointe Claire, CA Paris, FR München, DE Dublin, IE Milano, IT see more | Locations Novato, US HQ | |
Employees | Employees 109% decrease | Employees 58415% increase | Employees 1,2134% increase | Employees 74021% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 3 b | Valuation ($) 290.2 m | Valuation ($) 4.1 b |
Twitter followers | Twitter followers N/A | Twitter followers 2 k | Twitter followers 10.1 k | Twitter followers N/A |
Number of tweets (last 30 days) | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 10 | Number of tweets (last 30 days) 17 | Number of tweets (last 30 days) N/A |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 4.4 | Average likes per tweet (last 30 days) 7.8 | Average likes per tweet (last 30 days) N/A |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A |
Alexa Website Rank | Alexa Website Rank N/A | Alexa Website Rank 432054 | Alexa Website Rank 513212 | Alexa Website Rank N/A |
Employee Rating | Employee Rating N/A | Employee Rating 2.9 | Employee Rating 3.6 | Employee Rating 4.4 |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $260.9m (FY, 2020) | Revenue (est.) $250.7m (FY, 2020) | Revenue (est.) $271m (FY, 2020) |
Cost of goods | Cost of goods N/A | Cost of goods $31m (FY, 2020) | Cost of goods $5.4m (FY, 2020) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $229.8m (FY, 2020) | Gross profit $245.3m (FY, 2020) | Gross profit N/A |
Net income | Net income N/A | Net income ($276.9m) (FY, 2020) | Net income ($618.7m) (FY, 2020) | Net income ($186.6m) (FY, 2020) |
Funding | ||||
Total funding raised | Total funding raised $ 30m | Total funding raised $ 88m | Total funding raised $ 409m | Total funding raised $ 200.1m |
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
View companyBluebird Bio is a developer of gene therapies for severe genetic diseases and cancer.
View companyUltragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
View company